MAIDENHEAD, England--(BUSINESS WIRE)--Procognia Ltd announced today that it has entered into a collaboration with GlaxoSmithKline to explore the use of Procognia’s protein function arrays within the GSK drug development processes through a combination of Procognia’s functional protein array technology and GSK’s fluorescently-labelled broad-specificity kinase inhibitors.
